SOPHiA GENETICS (NASDAQ:SOPH) Trading Down 8.3% – Time to Sell?

SOPHiA GENETICS SA (NASDAQ:SOPH) fell 8.3% during trading on Wednesday . The stock traded as low as $7.69 and last traded at $7.6670. 591,292 shares traded hands during mid-day trading, an increase of 128% from the average session volume of 259,581 shares. The stock had previously closed at $8.36.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th. HC Wainwright raised their price objective on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. Zacks Research raised shares of SOPHiA GENETICS to a “hold” rating in a research note on Tuesday, July 21st. Finally, BTIG Research upped their target price on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $10.00.

SOPHiA GENETICS Stock Performance

The firm has a market capitalization of $639.75 million, a PE ratio of -6.63 and a beta of 0.98. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 0.58. The company has a 50-day moving average of $6.98 and a 200 day moving average of $5.67.

SOPHiA GENETICS (NASDAQ:SOPH) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.05). SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. The business had revenue of $23.31 million during the quarter, compared to analysts’ expectations of $21.72 million. Equities research analysts predict that SOPHiA GENETICS SA will post -0.77 EPS for the current year.

Insiders Place Their Bets

In other SOPHiA GENETICS news, insider Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $8.68, for a total transaction of $43,400.00. Following the completion of the sale, the insider directly owned 213,387 shares in the company, valued at $1,852,199.16. The trade was a 2.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CTO Abhimanyu Verma sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $8.80, for a total transaction of $44,000.00. Following the completion of the transaction, the chief technology officer directly owned 172,171 shares of the company’s stock, valued at approximately $1,515,104.80. This represents a 2.82% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 342,592 shares of company stock valued at $2,205,587 over the last three months. Corporate insiders own 4.88% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in SOPHiA GENETICS by 246.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock worth $25,341,000 after buying an additional 5,432,871 shares in the last quarter. AWM Investment Company Inc. bought a new position in SOPHiA GENETICS during the second quarter valued at approximately $9,809,000. Akre Capital Management LLC raised its stake in shares of SOPHiA GENETICS by 66.2% during the second quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock worth $11,529,000 after acquiring an additional 1,481,636 shares in the last quarter. Hodges Capital Management Inc. purchased a new position in shares of SOPHiA GENETICS during the first quarter worth approximately $2,157,000. Finally, Royce & Associates LP bought a new stake in shares of SOPHiA GENETICS in the 4th quarter worth approximately $2,009,000. 31.59% of the stock is currently owned by hedge funds and other institutional investors.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.